Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1819-1825

  Zhu, Hao Jie ^a,c   Appel, David I ^a,c   Jiang, Yan ^b   Markowitz, John S ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; HUMAN GROWTH HORMONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMAL EXPERIMENT; ARTICLE; CHILD; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; FEMALE; HUMAN; INFANT; LIVER; MALE; MOUSE; NEWBORN; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SEX DIFFERENCE; SEXUAL MATURATION;

ADOLESCENT; ADULT; AGED; AGING; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROLYSIS; INFANT; INFANT, NEWBORN; LIVER; MALE; METHYLPHENIDATE; MICE; MIDDLE AGED; SEX CHARACTERISTICS; SUBCELLULAR FRACTIONS; YOUNG ADULT;

ANIMALIA; MUS;

EID: 70349127799     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028209     Document Type: Article

References (37)

1. Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, and Robert J (2008) Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 61:481-488. (Pubitemid 350275983)
2. Benedetti MS, Whomsley R, and Canning M (2007) Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 12:599-610. (Pubitemid 47243707)
3. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, Saito T, Koga A, Muramatsu M, and Katagiri T (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 28:719-725. (Pubitemid 41723530)
4. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267.
5. Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Watanabe N, Tsukada E, Ohhata Y, Kobayashi K, Satoh T, and Chiba K (2008) Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 23:73-84.
6. Hosokawa M and Satoh T (1988) Effects of hypophysectomy and pituitary hormones on hepatic microsomal carboxylesterase isozymes in male rats. Res Commun Chem Pathol Pharmacol 62:279-288. (Pubitemid 19008046)
7. Imai T, Taketani M, Shii M, Hosokawa M, and Chiba K (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734-1741. (Pubitemid 44427476)
8. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
9. Jewell C, Bennett P, Mutch E, Ackermann C, and Williams FM (2007) Inter-individual variability in esterases in human liver. Biochem Pharmacol 74:932-939. (Pubitemid 47214626)
10. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, and Kauffman RE (2003) Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167.
11. Kennedy M (2008) Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther 84:662-673.
12. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965-974. (Pubitemid 38263972)
13. Leeder JS and Kearns GL (1997) Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 44:55-77.
14. Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438.
15. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
16. Mugford CA and Kedderis GL (1998) Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441-498.
17. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, and Markowitz JS (2007) Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346-353. (Pubitemid 46364487)
18. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661:133-141.
19. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, and Bosron WF (2004) Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]- carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 32:505-511.
20. Satoh T and Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38:257-288.
21. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493. (Pubitemid 34456967)
22. Scandlyn MJ, Stuart EC, and Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413-424.
23. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484. (Pubitemid 44776497)
24. Sonnier M and Cresteil T (1998) Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893-898. (Pubitemid 28108986)
25. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, and Zaya MJ (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573-582. (Pubitemid 37310671)
26. Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, and Hines RN (2008) Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36:1587-1593.
27. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, and Bosron WF (2004) Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310:469-476. (Pubitemid 38988889)
28. Takahashi S, Katoh M, Saitoh T, Nakajima M, and Yokoi T (2008) Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. J Pharm Sci 97:5434-5445.
29. Vieira I, Sonnier M, and Cresteil T (1996) Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238:476-483. (Pubitemid 126425464)
30. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, and Breese GR (1983) Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 226:382-386.
31. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, Wigal T, Kapelinski A, Martinez J, Modi NB, et al. (2007) Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:153-164. (Pubitemid 46828911)
32. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988. (Pubitemid 37221681)
33. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, and Yan B (2009) Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77:238-247.
34. Yang J, Shi D, Yang D, Song X, and Yan B (2007) Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 72:686-694. (Pubitemid 47347303)
35. Zhu HJ, Appel DI, Johnson JA, Chavin KD, and Markowitz JS (2009) Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol 77:1266-1272.
36. Zhu HJ and Markowitz JS (2009) Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 37:264-267.
37. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, et al. (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241-1248.